Hepatitis C Therapeutics in Major Developed Market would Grow from USD 5.9 billion in 2012 to USD 19 billion in 2019

Global hepatitis C therapeutics market would grow from USD 5.9 billion in 2012 to USD 19 billion in 2019. Hepatitis C, a complex liver disease, is caused by the ribonucleic acid virus. It usually spreads through direct contact with infected blood or blood products. Detection is very difficult as the infection is often asymptomatic.

Hepatitis C is of serious nature as even when detected and targeted, it continues to establish and maintain a life-long, persistent infection. This could result in cirrhosis and hepatocellular carcinoma. Hepatitis C is a leading cause of liver transplantation in North America and the U.K.

No preventive vaccine or selective antiviral therapy exists at present. Current treatment options include a combination of ribavirin and pegylated interferon. Patients diagnosed with genotype 1 hepatitis C are treated with one of two direct-acting antiviral agents (DAAs).

View summary of this report @ http://www.radiantinsights.com/research/hepatitis-c-therapeutics-in-major-developed-markets-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to-transform-clinical-and-commercial-landscape

However, these treatment options are not very effective. Moreover, these drugs are toxic and lead to side effects that include fever, depression, arthralgia, and haemolytic anemia. Also, their administration is a costly affair. Price of a single dose ranges between few hundred dollars to thousands of dollars. Also standard insurance covers do not reimburse complete costs.

The virus’s lifecycle is highly complicated, making discovery of new therapies a daunting task. DAA Sovaldi, which was approved in December 2013, has marked a breakthrough in this space. It achieved complete viral clearance in almost 100% of the patients. Additionally, instances of adverse events have been lower as compared to previous therapies. In cases of genotype 2 and 3 hepatitis C, Sovaldi need not be administered with pegylated interferon.

Download sample Copy of This Report at: http://www.radiantinsights.com/research/hepatitis-c-therapeutics-in-major-developed-markets-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to-transform-clinical-and-commercial-landscape#tabs-4

Apart from Sovaldi, several other products may be introduced in the near future. These are expected to provide better efficacy and safety. They include multiple interferon-free therapies for patients suffering from genotype 1 infection. These novel products would prove favorable for market growth. 

The growth potential is attracting several players in the healthcare drugs industry. Rising presence of Asian manufacturers will lead to cheaper products. North America is the largest market in terms of volumes, while Europe occupies second place. Demand in these markets is being driven by high incidence rates and affordability.

See More Reports of This Category by Radiant Insights:

·         France Anesthesia and Respiratory Devices Market Outlook to 2021 - Airway and Anesthesia Devices, Anesthesia Machines, Pain Management Devices, Regional Anesthesia Disposables, Respiratory Devices, Respiratory Disposables and Others - http://www.radiantinsights.com/research/france-anesthesia-and-respiratory-devices-market-outlook-to-2021-airway-and-anesthesia-devices-anesthesia-machines-pain-management-devices-regional-anesthesia-disposables-respiratory-devices-respiratory-disposables-and-others

·       

  Germany Anesthesia and Respiratory Devices Market Outlook to 2021 - Airway and Anesthesia Devices, Anesthesia Machines, Pain Management Devices, Regional Anesthesia Disposables, Respiratory Devices, Respiratory Disposables and Others – http://www.radiantinsights.com/research/germany-anesthesia-and-respiratory-devices-market-outlook-to-2021-airway-and-anesthesia-devices-anesthesia-machines-pain-management-devices-regional-anesthesia-disposables-respiratory-devices-respiratory-disposables-and-others

Table of Contents

Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 9

2 Introduction 10

2.1 Signs and Symptoms 10

2.2 Etiology and Risk Factors 11

2.3 Pathophysiology 11

2.4 Epidemiology 12

2.4.1 US and Canada 12

2.4.2 Europe 12

2.4.3 Japan 13

2.4.4 Regional Prevalence of Hepatitis C Genotypes 13

2.5 Prognosis 14

2.6 Diagnosis and Screening 16

2.7 Treatment 16

2.8 Treatment Algorithms 17

3 Marketed Products 21

3.1 Ribavirin 21

3.2 Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b) - Hoffmann La Roche and Merck & Co 22

3.2.1 Pegasys - Hoffmann La Roche 24

3.2.2 PegIntron - Merck & Co 24

3.3 Incivek (telaprevir) - Vertex Pharmaceuticals and Janssen-Cilag 25

3.4 Victrelis (boceprevir) - Merck & Co 26

3.5 Olysio (simeprevir) - Johnson and Johnson 27

3.6 Sovaldi (sofosbuvir) - Gilead Sciences 28

3.7 Heat Map for Marketed Products 29

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit Radiant Insights

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com  
Blog URL: http://www.radiantinsightsinc.blogspot.com